I hope you are all keeping well. Abstracts for the conference were due in by end of May 2021.
The programme for the conference is now available & abstracts are usually available prior to the conference, but E Posters embargoed until commencement. Hence the TH. The website for the conference is down at the moment, so they must be updating it. Take a look later today.
Below is the timeline for presentations pending from the Quarterly Activities Report in April 2021.
Following the presentation in Australia in August, we have a big one in EU in September, also for clinical data, which can only be Janssen study Ph2 also. It will be interesting to see what is presented next month in Australia vs the European conference. We were also looking at cardiovascular outcomes as well as DKD, so my guess is that the data presented in Australia will be built on for the European presentation. You can’t present the same poster twice at different conferences.
Then we have another big conference in November in USA, ASN (American Society of Nephrology) for clinical data.
This is a very complex and long study with a major Pharma, so need to TH. Positive to see that Janssen are co-presenting.
The timeline for inflection points this year is also an application to the TGA for PromarkerD here in Australia (we already are approved for export & the PromarkerD hub). So a good opportunity to present to Australian endocrinologists, GPs and other healthcare professionals involved in the care of diabetes patients.
There are 2 conferences being presented at next month, the other is AIMs which is a plenary talk on PromarkerD platforms (Medical Science).
Just my thoughts, & yes finally great to see some results. The lab stuff was completed quite a while ago now, so the data analysis has taken some time. We were warned it was a large complex study, looking at both long term DKD & CVD outcomes on treatment with Canafliglozin (Invokana).
In the time that this study has been running, there is a lot of new research out on SGLT2is & their benefits. Some of the research presented at the ADA was really interesting, & that should be published soon in journals. Will keep my eye out & post here.
GLTAH
PIQ Price at posting:
99.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)